211 related articles for article (PubMed ID: 28349991)
41. Investigating the Interaction of an Anticancer Nucleolipidic Ru(III) Complex with Human Serum Proteins: A Spectroscopic Study.
Riccardi C; Campanella A; Montesarchio D; Del Vecchio P; Oliva R; Paduano L
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985771
[TBL] [Abstract][Full Text] [Related]
42. Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.
Meier-Menches SM; Gerner C; Berger W; Hartinger CG; Keppler BK
Chem Soc Rev; 2018 Feb; 47(3):909-928. PubMed ID: 29170783
[TBL] [Abstract][Full Text] [Related]
43. Slow-targeted release of a ruthenium anticancer agent from vitamin B
Delasoie J; Rossier J; Haeni L; Rothen-Rutishauser B; Zobi F
Dalton Trans; 2018 Dec; 47(48):17221-17232. PubMed ID: 30302457
[TBL] [Abstract][Full Text] [Related]
44. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and cytotoxic activities of organometallic Ru(II) diamine complexes.
Kavukcu SB; Şahin O; Seda Vatansever H; Kurt FO; Korkmaz M; Kendirci R; Pelit L; Türkmen H
Bioorg Chem; 2020 Jun; 99():103793. PubMed ID: 32278205
[TBL] [Abstract][Full Text] [Related]
46. Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) β-carboline complexes.
Chen J; Peng F; Zhang Y; Li B; She J; Jie X; Zou Z; Chen M; Chen L
Eur J Med Chem; 2017 Nov; 140():104-117. PubMed ID: 28923379
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes.
Guo L; Hu X; Yang Y; An W; Gao J; Liu Q; Liu Z
Bioorg Chem; 2021 Nov; 116():105311. PubMed ID: 34474302
[TBL] [Abstract][Full Text] [Related]
48. Synthesis, characterization, in vitro cytotoxicity, and apoptosis-inducing properties of ruthenium(II) complexes.
Xu L; Zhong NJ; Xie YY; Huang HL; Jiang GB; Liu YJ
PLoS One; 2014; 9(5):e96082. PubMed ID: 24804832
[TBL] [Abstract][Full Text] [Related]
49. Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells.
Du J; Zhang E; Zhao Y; Zheng W; Zhang Y; Lin Y; Wang Z; Luo Q; Wu K; Wang F
Metallomics; 2015 Dec; 7(12):1573-83. PubMed ID: 26446567
[TBL] [Abstract][Full Text] [Related]
50. Ruthenium complexes with phenylterpyridine derivatives target cell membrane and trigger death receptors-mediated apoptosis in cancer cells.
Deng Z; Gao P; Yu L; Ma B; You Y; Chan L; Mei C; Chen T
Biomaterials; 2017 Jun; 129():111-126. PubMed ID: 28340357
[TBL] [Abstract][Full Text] [Related]
51. Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota S; Rodrigues DA; Crans DC; Barreiro EJ
J Med Chem; 2018 Jul; 61(14):5805-5821. PubMed ID: 29446940
[TBL] [Abstract][Full Text] [Related]
52. Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents.
Vajpayee V; Yang YJ; Kang SC; Kim H; Kim IS; Wang M; Stang PJ; Chi KW
Chem Commun (Camb); 2011 May; 47(18):5184-6. PubMed ID: 21451846
[TBL] [Abstract][Full Text] [Related]
53. An estrogen receptor targeted ruthenium complex as a two-photon photodynamic therapy agent for breast cancer cells.
Zhao X; Li M; Sun W; Fan J; Du J; Peng X
Chem Commun (Camb); 2018 Jun; 54(51):7038-7041. PubMed ID: 29873358
[TBL] [Abstract][Full Text] [Related]
54. Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.
Jayanthi E; Kalaiselvi S; Padma VV; Bhuvanesh NS; Dharmaraj N
Dalton Trans; 2016 Jan; 45(4):1693-707. PubMed ID: 26699435
[TBL] [Abstract][Full Text] [Related]
55. Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.
Chow MJ; Licona C; Yuan Qiang Wong D; Pastorin G; Gaiddon C; Ang WH
J Med Chem; 2014 Jul; 57(14):6043-59. PubMed ID: 25023617
[TBL] [Abstract][Full Text] [Related]
56. Ruthenium(II)-Arene Thiocarboxylates: Identification of a Stable Dimer Selectively Cytotoxic to Invasive Breast Cancer Cells.
Stephens LJ; Levina A; Trinh I; Blair VL; Werrett MV; Lay PA; Andrews PC
Chembiochem; 2020 Apr; 21(8):1188-1200. PubMed ID: 31701616
[TBL] [Abstract][Full Text] [Related]
57. Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes.
Holder AA; Taylor P; Magnusen AR; Moffett ET; Meyer K; Hong Y; Ramsdale SE; Gordon M; Stubbs J; Seymour LA; Acharya D; Weber RT; Smith PF; Dismukes GC; Ji P; Menocal L; Bai F; Williams JL; Cropek DM; Jarrett WL
Dalton Trans; 2013 Sep; 42(33):11881-99. PubMed ID: 23783642
[TBL] [Abstract][Full Text] [Related]
58. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F
Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415
[TBL] [Abstract][Full Text] [Related]
59. Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes.
Chow MJ; Babak MV; Wong DY; Pastorin G; Gaiddon C; Ang WH
Mol Pharm; 2016 Jul; 13(7):2543-54. PubMed ID: 27174050
[TBL] [Abstract][Full Text] [Related]
60. Synthesis, visible light photocleavage, antiproliferative and cellular uptake properties of ruthenium complex [Ru(phen)2(mitatp)]2+.
Yu HJ; Chen Y; Yu L; Hao ZF; Zhou LH
Eur J Med Chem; 2012 Sep; 55():146-54. PubMed ID: 22841281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
